Perner F, Perner C, Ernst T, Heidel FH. Roles of JAK2 in aging, inflammation, hematopoiesis and malignant transformation. Cells. 2019:8:854.

Perner F, Pahl HL, Zeiser R, Heidel FH. Malignant JAK-signaling: at the interface of inflammation and malignant transformation. Leukemia. 2025;39:1011–30.

Tefferi A, Barbui T. Polycythemia vera: 2024 update on diagnosis, risk-stratification, and management. Am J Hematol. 2023;98:1465–87.

Article  CAS  PubMed  Google Scholar 

Masarova L, Chifotides HT. SOHO state of the art update and next questions: novel therapies for polycythemia vera. Clin Lymphoma Myeloma Leuk. 2024;24:141–8.

Article  CAS  PubMed  Google Scholar 

Hultcrantz M, Björkholm M, Dickman PW, Landgren O, Derolf ÅR, Kristinsson SY, et al. Risk for arterial and venous thrombosis in patients with myeloproliferative neoplasms: a population-based cohort study. Ann Intern Med. 2018;168:317–25.

Article  PubMed  PubMed Central  Google Scholar 

Landolfi R, Di Gennaro L, Barbui T, De Stefano V, Finazzi G, Marfisi R, et al. Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera. Blood. 2007;109:2446–52.

Article  CAS  PubMed  Google Scholar 

Finazzi G. A prospective analysis of thrombotic events in the European collaboration study on low-dose aspirin in polycythemia (ECLAP). Pathol Biol. 2004;52:285–8.

Article  CAS  PubMed  Google Scholar 

Enblom-Larsson A, Renlund H, Andréasson B, Holmberg H, Liljeholm M, Själander A. Thromboembolic events, major bleeding and mortality in essential thrombocythaemia and polycythaemia vera—a matched nationwide population-based study. Br J Haematol. 2024;204:1740–51.

Article  CAS  PubMed  Google Scholar 

Cerquozzi S, Barraco D, Lasho T, Finke C, Hanson CA, Ketterling RP, et al. Risk factors for arterial versus venous thrombosis in polycythemia vera: a single center experience in 587 patients. Blood Cancer J. 2017;7:1–7.

Article  Google Scholar 

Barbui T, Carobbio A, Rumi E, Finazzi G, Gisslinger H, Rodeghiero F, et al. In contemporary patients with polycythemia vera, rates of thrombosis and risk factors delineate a new clinical epidemiology. Blood. 2014;124:3021–3.

Article  PubMed  Google Scholar 

Barbui T, Tefferi A, Vannucchi AM, Passamonti F, Silver RT, Hoffman R, et al. Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet. Leukemia. 2018;32:1057–69.

Article  PubMed  PubMed Central  Google Scholar 

Guglielmelli P, Mora B, Gesullo F, Mannelli F, Loscocco GG, Signori L, et al. Clinical impact of mutated JAK2 allele burden reduction in polycythemia vera and essential thrombocythemia. Am J Hematol. 2024;99:1550–9.

Article  CAS  PubMed  Google Scholar 

Guglielmelli P, Loscocco GG, Mannarelli C, Rossi E, Mannelli F, Ramundo F, et al. JAK2V617F variant allele frequency >50% identifies patients with polycythemia vera at high risk for venous thrombosis. Blood Cancer J. 2021;11:199.

Barbui T, Carobbio A, Guglielmelli P, Ghirardi A, Fenili F, Loscocco GG, et al. Neutrophil/lymphocyte ratio identifies low-risk polycythaemia vera patients for early Ropeginterferon alfa-2b therapy. Br J Haematol. 2024;205:2287–94.

Verstovsek S, Krečak I, Heidel FH, De Stefano V, Bryan K, Zuurman MW, et al. Identifying patients with polycythemia vera at risk of thrombosis after hydroxyurea initiation: the Polycythemia Vera-Advanced Integrated Models (PV-AIM) Project. Biomedicines. 2023;11:1925.

Marchetti M, Vannucchi AM, Griesshammer M, Harrison C, Koschmieder S, Gisslinger H, et al. Appropriate management of polycythaemia vera with cytoreductive drug therapy: European LeukemiaNet 2021 recommendations. Lancet Haematol. 2022;9:e301–11.

Article  CAS  PubMed  Google Scholar 

Crodel CC, Jentsch-Ullrich K, Reiser M, Jacobasch L, Sauer A, Tesch H, et al. Cytoreductive treatment in real life: a chart review analysis on 1440 patients with polycythemia vera. J Cancer Res Clin Oncol. 2022;148:2693–705.

Article  PubMed  Google Scholar 

Jentsch-Ullrich K, Eberhardt J, Zeremski V, Koehler M, Wolleschak D, Heidel FH. Characteristics and treatment of polycythemia vera patients in clinical practice: a multicenter chart review on 1476 individuals in Germany. J Cancer Res Clin Oncol. 2016;142:2041–9.

Article  CAS  PubMed  Google Scholar 

Palandri F, Rossi E, Auteri G, Breccia M, Paglia S, Benevolo G, et al. Predictors of response to hydroxyurea and switch to ruxolitinib in HU-resistant polycythaemia VERA patients: a real-world PV-NET study. Cancers. 2023;15:3706.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Podoltsev NA, Zhu M, Zeidan AM, Wang R, Wang X, Davidoff AJ, et al. The impact of phlebotomy and hydroxyurea on survival and risk of thrombosis among older patients with polycythemia vera. Blood Adv. 2018;2:2681.

Article  PubMed  PubMed Central  Google Scholar 

Gilbert HS. Current management in polycythemia vera. Semin Hematol. 2001;38:25–8.

Article  CAS  PubMed  Google Scholar 

Arber DA, Orazi A, Hasserjian RP, Borowitz MJ, Calvo KR, Kvasnicka HM, et al. International consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022;140:1200–28.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Barosi G, Mesa RA, Thiele J, Cervantes F, Campbell PJ, Verstovsek S, et al. Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment. Leukemia. 2008;22:437–8.

Article  CAS  PubMed  Google Scholar 

Mora B, Passamonti F. SOHO state of the art updates and next questions | polycythemia vera: is it time to rethink treatment?. Clin Lymphoma Myeloma Leuk. 2023;23:79–85.

Article  CAS  PubMed  Google Scholar 

Slee VN. The International Classification of Diseases: ninth revision (ICD-9). Ann Intern Med. 1978;88:424–6.

Article  CAS  PubMed  Google Scholar 

Cancer Institute N. Common Terminology Criteria for Adverse Events (CTCAE) Common Terminology Criteria for Adverse Events (CTCAE) v5.0. 2017.

Marchioli R, Finazzi G, Specchia G, Masciulli A, Mennitto MR, Barbui T. The CYTO-PV: a large-scale trial testing the intensity of CYTOreductive therapy to prevent cardiovascular events in patients with polycythemia vera. Thrombosis. 2011;2011:1–9.

Article  Google Scholar 

Greenlund KJ, Zheng ZJ, Keenan NL, Giles WH, Casper ML, Mensah GA, et al. Trends in self-reported multiple cardiovascular disease risk factors among adults in the United States, 1991-1999. Arch Intern Med. 2004;164:181–8.

Article  PubMed  Google Scholar 

Tsao CW, Vasan RS. Cohort profile: the Framingham Heart Study (FHS): overview of milestones in cardiovascular epidemiology. Int J Epidemiol. 2015;44:1800–13.

Article  PubMed  PubMed Central  Google Scholar 

Emanuel RM, Dueck AC, Geyer HL, Kiladjian JJ, Slot S, Zweegman S, et al. Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs. J Clin Oncol. 2012;30:4098–103.

Article  PubMed  PubMed Central  Google Scholar 

De Stefano V, Za T, Rossi E, Vannucchi AM, Ruggeri M, Elli E, et al. Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments. Haematologica. 2008;93:372–80.

Article  PubMed  Google Scholar 

Ferrari A, Carobbio A, Masciulli A, Ghirardi A, Finazzi G, de Stefano V, et al. Clinical outcomes under hydroxyurea treatment in polycythemia vera: a systematic review and meta-analysis. Haematologica. 2019;104:2391–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

De Stefano V, Rossi E, Carobbio A, Ghirardi A, Betti S, Finazzi G, et al. Hydroxyurea prevents arterial and late venous thrombotic recurrences in patients with myeloproliferative neoplasms but fails in the splanchnic venous district. Pooled analysis of 1500 cases. Blood Cancer J. 2018;8:1–7.

Article  Google Scholar 

Barbui T, De Stefano V, Ghirardi A, Masciulli A, Finazzi G, Vannucchi AM. Different effect of hydroxyurea and phlebotomy on prevention of arterial and venous thrombosis in Polycythemia Vera. Blood Cancer J. 2018;8:124.

Mascarenhas J, Kosiorek HE, Prchal JT, Rambaldi A, Berenzon D, Yacoub A, et al. A randomized phase 3 trial of interferon-α vs hydroxyurea in polycythemia vera and essential thrombocythemia. Blood. 2022;139:2931–41.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Silver RT. Long-term effects of the treatment of polycythemia vera with recombinant interferon-α. Cancer. 2006;107:451–8.

Article  CAS  PubMed  Google Scholar 

Them NCC, Bagienski K, Berg T, Gisslinger B, Schalling M, Chen D, et al. Molecular responses and chromosomal aberrations in patients with polycythemia vera treated with peg-proline-interferon alpha-2b. Am J Hematol. 2015;90:288–94.